IN8BIO, Inc.
INAB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001740279
No open-market purchases or sales by IN8BIO, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $5.35M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in IN8BIO, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- 0 vs. Q4 2021
- Shares held
- 2.05M
- +271.6K (+15.3%) vs. Q4 2021
- Total value
- $7.02M
- −$784.0K (−10.0%) vs. Q4 2021
- New holders
- 1
- 8 more added
- Sold out
- 1
- 2 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INAB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 21 | $5.35M |
| Q1 2026 | 19 | $5.55M |
| Q4 2025 | 22 | $7.45M |
| Q3 2025 | 19 | $2.13M |
| Q2 2025 | 12 | $1.83M |
| Q1 2025 | 28 | $3.60M |
| Q4 2024 | 26 | $7.72M |
| Q3 2024 | 26 | $2.06M |
| Q2 2024 | 26 | $6.77M |
| Q1 2024 | 32 | $10.2M |
| Q4 2023 | 30 | $11.4M |
| Q3 2023 | 21 | $2.58M |
| Q2 2023 | 22 | $3.59M |
| Q1 2023 | 17 | $1.78M |
| Q4 2022 | 16 | $2.79M |
| Q3 2022 | 17 | $2.42M |
| Q2 2022 | 15 | $5.50M |
| Q1 2022 | 14 | $7.02M |
| Q4 2021 | 14 | $7.80M |
| Q3 2021 | 13 | $12.2M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding IN8BIO, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Capital World Investors | 800,000 | $2.78M | 0.00% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 352,753 | $1.23M | 0.08% | −20,416−5.5% | Reduced |
| Voss Capital, LLC | 259,003 | $875.0K | 0.27% | +157,224+154.5% | Added |
| B. Riley Financial, Inc. | 257,513 | $858.0K | 0.15% | +135+0.1% | Added |
| Vanguard Group Inc | 111,493 | $372.0K | 0.00% | −8,723−7.3% | Reduced |
| Sigma Planning Corp | 97,750 | $326.0K | 0.01% | +69,150+241.8% | Added |
| Ensign Peak Advisors, Inc | 70,028 | $243.0K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 60,000 | $208.0K | 0.00% | +60,000 | New |
| BlackRock Inc. | 16,334 | $54.0K | 0.00% | +6,773+70.8% | Added |
| HighTower Advisors, LLC | 14,164 | $47.0K | 0.00% | +4,164+41.6% | Added |
| UBS Group AG | 3,841 | $13.0K | 0.00% | +2,107+121.5% | Added |
| Tower Research Capital LLC (TRC) | 3,395 | $11.0K | 0.00% | +219+6.9% | Added |
| Morgan Stanley | 2,921 | $10.0K | 0.00% | +993+51.5% | Added |
| Wells Fargo & Company | 24 | $0 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 0 | $0 | 0.00% | −7−100.0% | Sold out |